This study focused on the factors related to HB recurrence and found the following risk factors in this study: patient age older than 54 months, AFP that decreased by less than 60% after the patient received neoadjuvant chemotherapy, tumour size that failed to achieve partial remission after neoadjuvant chemotherapy, and AFP that failed to return to a normal range within 6 months after receiving treatment. The gene discussed is AFP; the disease is hemoglobin measurement.